Stephens Consulting’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$709K Buy
3,426
+25
+0.7% +$4.94K 0.23% 28
2025
Q3
$631K Sell
3,401
-771
-18% -$132K 0.22% 30
2025
Q2
$637K Sell
4,172
-542
-11% -$83.3K 0.15% 54
2025
Q1
$782K Buy
4,714
+571
+14% +$89.3K 0.2% 45
2024
Q4
$599K Buy
4,143
+349
+9% +$54.1K 0.15% 52
2024
Q3
$615K Sell
3,794
-143
-4% -$22.8K 0.16% 51
2024
Q2
$575K Buy
3,937
+180
+5% +$26.8K 0.16% 47
2024
Q1
$594K Sell
3,757
-474
-11% -$75.4K 0.18% 42
2023
Q4
$663K Buy
4,231
+1
+0% +$153 0.22% 39
2023
Q3
$659K Buy
4,230
+1
+0% +$165 0.27% 37
2023
Q2
$700K Sell
4,229
-88
-2% -$14.2K 0.28% 37
2023
Q1
$669K Sell
4,317
-401
-8% -$64.8K 0.4% 37
2022
Q4
$833K Buy
4,718
+1
+0% +$173 0.55% 31
2022
Q3
$771K Sell
4,717
-91
-2% -$15.4K 0.69% 27
2022
Q2
$854K Buy
4,808
+30
+0.6% +$5.34K 0.69% 24
2022
Q1
$847K Sell
4,778
-1,004
-17% -$171K 0.69% 28
2021
Q4
$989K Buy
+5,782
New +$947K 0.82% 27

Other funds holding JNJ

Stephens Consulting's JNJ Position: Q4 2025 in Review

Stephens Consulting increased its Johnson & Johnson (JNJ) stake by 0.74% in Q4 2025, buying an estimated $4.94K and bringing the position to 3,426 shares worth $709K. The position accounts for 0.23% of the portfolio, ranked #28.

Stephens Consulting first reported a position in JNJ in Q4 2021 and has held it in 17 quarters since. The position peaked at $989K in Q4 2021. 4,520 funds tracked by Wall St. Rank hold JNJ as of Q4 2025.

  • Stephens Consulting held 3,426 shares of Johnson & Johnson worth $709K as of Q4 2025.
  • Stephens Consulting bought 25 Johnson & Johnson shares in Q4 2025, an estimated $4.94K.
  • Johnson & Johnson made up 0.23% of Stephens Consulting's portfolio in Q4 2025, its #28 holding.
  • Stephens Consulting first reported a position in Johnson & Johnson in Q4 2021 and has held it in 17 quarters since.
  • Stephens Consulting's Johnson & Johnson position peaked at $989K in Q4 2021.
  • 4,520 funds tracked by Wall St. Rank held Johnson & Johnson as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.